News & Updates
Excerpt from the Announcement: The Cancer Therapeutics Innovation Pipeline (CTIP) Program was established to capitalize on Ontario’s expertise in cancer biology and drug discovery to create a pipeline of validated cancer targets and first-in-class or best-in-class, novel, selective lead molecules (small molecules or biologics) that would attract partnerships and/or investment for further preclinical and clinical…
Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., May 25, 2021 (GLOBE NEWSWIRE) — Senti Bio, a leading gene circuit company, today announced presentations on its gene circuit engineered allogeneic CAR-NK cell therapy pipeline at the International Society for Cell and Gene Therapy (ISCT) Virtual Annual Meeting. The presentations provide details of Senti Bio’s…
Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that its Sofia® SARS Antigen FIA is the first rapid antigen test to receive authorization from Health Canada for serial testing for the detection of active…
Excerpt from the Press Release: BOSTON–(BUSINESS WIRE)–AVEO Oncology (Nasdaq: AVEO), a commercial and clinical development stage biopharmaceutical company, today announced results from a randomized confirmatory Phase 2 study of ficlatuzumab as a single agent or in combination with cetuximab (ERBITUX®), an EGFR-targeted antibody, in patients who relapsed or were refractory to prior immunotherapy, chemotherapy, and…
Excerpt from the Article: Pennsylvania-based Ocugen has moved one step closer to bringing a COVID-19 vaccine developed by India-based Bharat Biotech into the United States market. The company submitted a “Master File” to the U.S., Food and Drug Administration, a necessary step ahead of seeking Emergency Use Authorization. Ocugen and Bharat Biotech have been working together since December to develop COVAXIN,…
Excerpt from the Press Release: PRINCETON, N.J., May 19, 2021 (GLOBE NEWSWIRE) — Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products today announced updated data from the Company’s ongoing Phase 1/2 study evaluating ADXS-503 in combination with KEYTRUDA® which will be presented as a poster at the American…
Excerpt from the Press Release: WAYNE, Pa., May 26, 2021 /PRNewswire/ — NFlection Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of targeted therapies for rare disorders driven by aberrant activation of the RAS pathway (RASopathies), today announced positive results from a 28-day, Phase 2a, multicenter, randomized, double-blind, parallel-group, vehicle-controlled clinical trial investigating the safety, tolerability,…
Excerpt from the Press Release: SARASOTA, Fla. and NOVATO, Calif., May 19, 2021 (GLOBE NEWSWIRE) — GeneTx Biotherapeutics LLC and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), companies partnered in the development of intrathecally administered GTX-102, an investigational treatment for Angelman syndrome, today announced that they have received clearance from Health Canada to begin enrolling the Phase…
Excerpt from the Press Release: BURLINGTON, Mass. & OXFORD, England–(BUSINESS WIRE)–Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, is pleased to share news of the publication of a study from researchers at Winship Cancer Institute of Emory University (Winship) evaluating Axumin® (fluciclovine F 18) PET…
Excerpt from the Press Release: Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announces positive topline results from the head-to-head phase 3 OCEAN study evaluating the efficacy and safety of melphalan flufenamide versus pomalidomide in patients with relapsed refractory multiple myeloma (RRMM).…
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?